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Altered states: psilocybin for treatment-resistant depression
“Alice remained looking thoughtfully at the mushroom 
for a minute, trying to make out which were the two 
sides of it; and as it was perfectly round, she found this 
a very diﬃ  cult question”. To resolve the issue, Alice 
ate the mushroom; in more recent times, however, 
experimentation with psilocybin-containing magic 
mushrooms has been strongly discouraged. In the 
UK, in 2005, magic mushrooms were classiﬁ ed as a 
Class A substance, with then Home Oﬃ  ce Minister 
Paul Goggins commenting: “Magic mushrooms are 
a powerful hallucinogen and can cause real harm, 
especially to vulnerable people and those with mental 
health problems”.1 
In this context, Robin Carhart-Harris and colleagues2 
deserve much praise for eﬀ ectively and safely 
completing an important clinical investigation into the 
eﬀ ect of psilocybin on treatment-resistant depression, 
in the face of many regulatory and practical hurdles. 
Findings from their study—an uncontrolled trial in which 
12 patients were given two doses of psilocybin 7 days 
apart, reported in The Lancet Psychiatry—support the 
feasibility and safety of this protocol, with preliminary 
eﬃ  cacy data suggesting an antidepressant eﬀ ect. Of 
course, great thanks are due to the participants; their 
description of the lived experience of the study and the 
aspects they found most beneﬁ cial will, when published, 
add substantially to assessment of the intervention.
New treatments for the substantial proportion (perhaps 
20%) of patients with depression who do not recover 
well with either cognitive psychotherapy or medication 
are certainly needed.3 Unfortunately, the development 
of new, more eﬀ ective medicines through the usual 
industry-led process of drug discovery has stalled. 
Intriguingly, into this void have come some repurposed 
older drugs, for example ketamine,4 scopolamine,5 
and nitrous oxide;6 by contrast with conventional 
antidepressants, these drugs produce rapid and profound 
changes in mood and consciousness. Ketamine has 
been the most studied and, although rapid alleviation 
of mood is reported in a reasonable proportion of 
patients, the eﬀ ects are relatively transient and disappear 
after a few days as the pharmacological eﬀ ect wanes.4 
The concept underlying the use of psychedelic agents 
such as psilocybin seems quite diﬀ erent, namely that 
administration of one or two doses results in profound, 
spiritually meaningful experiences that produce enduring 
gains in wellbeing and personal adjustment.7 Such eﬀ ects 
have not been studied systematically in patients with 
depression previously, but beneﬁ ts have been claimed 
following the use of psilocybin to treat anxiety and 
distress during end-of-life care, and in patients with 
alcohol and nicotine dependence.7  
How typical were the patients studied of those seen 
more generally with resistant depression? They were 
perhaps better educated than the average sample, with 
ten of the 12 participants having obtained at least an 
undergraduate degree. Unlike patients in secondary 
care, they seemed to have received little in the way 
of more conventional treatment strategies for severe 
chronic depression, for example pharmacological 
augmentation with lithium, atypical antipsychotic 
drugs, or the use of el ectroconvulsive therapy. Thus, 
although the patients met current criteria for treatment 
resistance, they would not generally be considered as 
treatment refractory by specialists.3  
Perhaps the most important feature of the patient 
group is that most self-selected for the investigation, 
with ﬁ ve of the 12 participants reporting previous 
use of psilocybin. Presumably, these participants had 
experienced a positive psychological response to 
psilocybin previously, and believed that the drug could 
help them. This is signiﬁ cant in an open-label study 
because, as acknowledged by the authors, it increases 
the likelihood of expectancy eﬀ ects. Perhaps related 
to this factor was the substantial clinical response 
to the ﬁ rst low-dose treatment of 10 mg psilocybin. 
Detailed data are not provided, probably because the 
Carhart-Harris and colleagues regarded the two doses of 
psilocybin (given 1 week apart) as a treatment package. 
However, the reduction in score on the Hamilton 
Depression Scale of around 10 points at 1 week after the 
low dose suggests a powerful antidepressant eﬀ ect of 
a moderate psychedelic experience. Might the patients 
have done as well on the low-dose treatment given 
alone? Although the present data make it diﬃ  cult to 
answer this question, it does point to a possible way in 
which future studies might be controlled by comparing 
the eﬀ ect of low and standard doses of psilocybin 
in patients with depression who have no previous 
exposure to psychedelic drugs. 
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A better understanding of the link between depression 
and dementia is essential, given the rapid growth of 
the elderly population, with an anticipated doubling 
of global dementia prevalence every 20 years.1 In the 
Lancet Psychiatry, the ﬁ ndings presented from the 
study by Saira Mirza and colleagues2 have brought us 
one step closer to answering whether depression is a 
risk factor for dementia or vice versa. They assessed 
diﬀ erent trajectories of depressive symptoms and 
their association with subsequent dementia in a large 
community sample of older adults over the course of 
10 years. The beauty of their study is the identiﬁ cation 
of ﬁ ve diﬀ erent depression trajectories: stable low, 
decreasing, remitting, increasing, or stable high 
depressive symptoms over ten years. With results 
analysed by a Cox proportional hazards model adjusted 
for age, sex, APOEε4 carrier status, educational level, 
body-mass index, smoking, alcohol consumption, 
The key observation that might eventually justify 
the use of a drug like psilocybin in treatment-resistant 
depression is demonstration of sustained beneﬁ t in 
patients who previously have experienced years of 
symptoms despite conventional treatments, which 
makes longer-term outcomes particularly important. 
The data at 3 month follow-up (a comparatively 
short time in patients with extensive illness duration) 
are promising but not completely compelling, with 
about half the group showing signiﬁ cant depressive 
symptoms. Further follow-ups using detailed qualitative 
interviews with patients and family could be very helpful 
in enriching the assessment.
Dramatic physical treatments in psychiatry come with 
a historical health warning, with insulin coma therapy 
as an oft-cited example. Relative to other misused 
substances, magic mushrooms have a low risk of harms 
such as dependence,8 but there are unwanted eﬀ ects, 
including acute anxiety and paranoia together with 
the possibility of longer-term adverse consequences on 
mental health in the psychologically vulnerable.9 In this 
respect, Carhart-Harris and colleagues provide a good 
framework for the safe conduct of psilocybin studies 
that follow guidelines established by researchers at 
Johns Hopkins University.9
The possible therapeutic use of psilocybin in 
treatment-resistant depression comes at a time of 
intense debate about the harms of recreational drug 
use and the role of government and the criminal justice 
system in regulation. Most clinicians will be pragmatic 
and ask whether beneﬁ ts substantially outweigh harms. 
This equation will include the diﬃ  culties of using a drug 
whose crucial positive psychological eﬀ ects are likely 
to be exquisitely sensitive to individual disposition, 
environmental setting, and therapeutic relationship 
(the author Edna O’Brien describes a petrifying LSD 
psychotherapy session with RD Laing, during which the 
famous anti-psychiatrist metamorphosed into a rat).10 
Patients with treatment-resistant depression seeking 
psychological insight with a less exciting trajectory 
might consider the slow route oﬀ ered by traditional 
dynamic psychotherapy.11
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Depression in old age—the ﬁ rst step to dementia?
